XOMA 358 First-in-Human study
19 evidence topics · 7 sources
Objective
Location and study date
First participant dosed in October 2014
Study design
Double-blind, placebo-controlled, single ascending dose
Eligibility criteria
Treatment
Single intravenous infusion of placebo or 0.1 to 9 mg/kg
Study outcomes
Rationale for using safety and tolerability as the primary endpoint
Purpose of the first-in-human study: safety, pharmacokinetics, and dose selection
Pharmacodynamic endpoints: insulin tolerance test and mixed meal test
Statistical analysis description
Number of participants (Planned and analyzed)
Interim count at the March 2015 presentation
Healthy volunteer count across phase 1 studies stated in the RIZE publication
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Pharmacokinetics: dose-proportional exposure and half-life
Pharmacodynamics: insulin as a biomarker of exposure and reduced insulin sensitivity
“Dose-dependent elevations of circulating insulin levels, likely related to reduced insulin clearance via monoclonal antibody action at receptors, represented a sensitive biomarker of X358 exposure. X358-dependent increases in postprandial glucose levels and fasting homeostatic model assessment of insulin resistance values were observed and persisted for at least 1 week at the higher dose levels. In all the ITT cohorts, the slope for glucose lowering was substantially attenuated after X358 infusion of a similar magnitude, but with increasing duration with rising dose level.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Single X358 infusions were well tolerated and resulted in a dose-dependent reduction in insulin sensitivity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamics at the interim presentation: postprandial glucose and insulin challenge
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No deaths, serious adverse events, or discontinuations due to adverse events
Tolerability at the interim presentation
Clinical testing limited to single-dose studies in adults after phase 1
Study limitations
Summary
- The study enrolled only healthy adult males and gave single doses, so it describes pharmacokinetics, pharmacodynamics, and short-term tolerability without information on repeated dosing or on patients with hyperinsulinism.
- Only the abstract and company releases are openly available; the full text, with eligibility, disposition, baseline characteristics, and adverse event tables, is closed access, and no registry identifier was found. The reported number of healthy volunteers differs across documents (29 in the publication; 22 across two phase 1 studies in a later publication).